Biosimilars – HCP
Biosimilars – HCP supports healthcare professionals through independent education on biosimilar concepts, approval, and treatment options to strengthen their knowledge and confidence in biosimilar use.
Funder: Teva
Due Dates: At least 60 days before the required decision date and activity start (completed request)
Funding Amounts: Not specified
Summary: Supports healthcare professional education on biosimilar concepts, approval, interchangeability, concentrations, and current and emerging adalimumab options.
Key Information: Grants are for educational organizations, not individuals, including individual healthcare professionals.
Description
Teva’s Biosimilars – HCP grant supports independent education that builds healthcare professionals’ knowledge of biosimilars and confidence in their use. Educational objectives include explaining what biosimilars are, clarifying terminology, describing the regulatory approval process, and increasing understanding of their role in healthcare. The program also seeks to strengthen understanding of interchangeability, different concentrations, and the attributes of current and emerging adalimumab biosimilars as treatment options.
The intended audience includes dermatologists, gastroenterologists, primary care physicians, rheumatologists, nurses, nurse practitioners, physician assistants, pharmacists, and managed care healthcare professionals. Teva supports evidence-based, clinically relevant, performance-based education. Accredited and non-accredited professional education programs may be considered, including symposia and web activities.
